6th May 2016 07:37
LONDON (Alliance News) - Gene and cell therapy company Oxford Biomedica PLC on Friday said two sets of test data have been released demonstrating long-term gene expression with its LentiVector platform.
The company said Professor Stéphane Palfi presented a poster on the company OXB-101 gene therapy treatment for Parkinson's disease at the American Society of Gene & Cell Therapy meeting in Washington, DC this week.
OXB-101 demonstrated a good safety profile and a statistically significant improvement in motor function in those treated relative to baseline after 6 and 12 months, the company said.
Also last week, Dr Andreas Lauer gave a presentation on a LentiVector-based treatment for neovascular age-related related macular degeneration, at the Association for Research in Vision & Ophthalmology conference in Seattle.
This also showed LentiVector gene expression was dose-dependent and continued without significant decline for more than four years.
"We are very encouraged by the demonstration of long-term expression and clinical benefit in patients indicated by the four-year follow-up data from these two clinical studies," said Oxford Biomedica Chief Executive John Dawson.
"We believe this is the first time gene therapy products have been directly measured in the eye and the longevity in both expression and efficacy to date reinforces the benefits of the company's pioneering LentiVector gene delivery platform in the treatment of chronic conditions," he added.
Oxford Biomedica shares were up 4.8% to 5.82 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica